Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
AngioDynamics
Latham, New York, United Statesangiodynamics.com ↗
- Ownership
- Public · ANGO
- Employees
- ~1200
- Development stage
- Other
01
Overview
Recent clinical results include the APEX-AV trial for the AlphaVac F18 85 System, which demonstrated safety and efficacy in treating patients with pulmonary embolism. The trial showed a decrease of 0.45 in the RV/LV ratio at 48 hours, surpassing the expected improvement of 0.12, with major adverse events occurring in only 4.1% of cases compared to the expected 25%[8].
- Therapeutic areas
- OncologyCardiovascular
- Modalities
- Minimally invasive medical devices
- Industry
- Surgical Medical Devices
02
Partnerships
Pulmonary Embolism Response Team (PERT) Consortium
03
Financials
- Market cap
- $496.7M
- Total revenue
- $320.2M
- Enterprise value
- $473.4M
Beyond the preview
Go deeper on AngioDynamics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AngioDynamics.